Orthocell

28/05/2026

Orthocell Ltd (ASX:OCC) is proud to be a Gold Sponsor of the Washington University Nerve Course, run by the Global Nerve Foundation (GNF) and WashU Medicine taking place May 29–30 in St Louis.

This two‑day program brings together leading surgeons for advanced training in peripheral nerve repair and reconstruction — an important opportunity to share knowledge that strengthens clinical practice and improves patient outcomes.

We look forward to connecting with colleagues in St Louis.

Learn more about the course here: https://bit.ly/4308ywW

28/05/2026

Orthocell has been featured in Stockhead, in an article exploring how ASX‑listed medical device companies are progressing in the US market following FDA approvals.

The piece highlights the growing global demand for innovative regenerative medicine solutions and the role Australian companies are playing in advancing patient care.

Read the full article here: https://bit.ly/4f722M2

$OCC hashtag hashtag hashtag hashtag hashtag

26/05/2026

From surgeon education and clinical engagement to investor discussions, our team is preparing for a strong lineup of upcoming industry events across Australia and New Zealand.

📍 Orthocell Nerve Symposium
12 June | Sydney
Now in its fourth year, the Orthocell Nerve Symposium is an advanced educational program designed to provide Orthopaedic and Plastic Surgeons with a broad understanding of peripheral nerve repair and regeneration, including nerve transfer techniques using our collagen-based nerve repair technology, Remplir™. Featuring an international faculty, cadaveric workshops and clinical discussions focused on improving surgical decision-making and patient outcomes.

📍 Plastic Surgery Congress (PSC)
24–25 July | Brisbane
One of Australia’s leading plastic and reconstructive surgery meetings, bringing together surgeons and industry from across the sector. Orthocell’s distribution partner, Device Technologies, will be showcasing Remplir™ throughout the event.

📍 20th Bioshares Biotech Summit
6–7 August | Queenstown, New Zealand
Our executive team will be heading across the Tasman for Bioshares, a key biotech and healthcare investment forum connecting emerging companies with investors and sector stakeholders.

We look forward to seeing you there.

21/05/2026

Orthocell CEO Paul Anderson recently joined the ASX Briefs podcast to discuss the Company’s strong commercial momentum and global expansion.

In the episode, Paul shares how Orthocell is entering a high-growth revenue phase, supported by record Q3 FY26 revenue, rapid US adoption of Remplir™ and growing hospital access across key markets.

Orthocell’s regenerative medicine platforms supports the repair of bones, nerves and tendons, and including Remplir™, its breakthrough collagen nerve repair product.

🎧 Listen to the full podcast here: https://open.spotify.com/episode/3sCKlChI4a1xZGzSrC3QUi?si=qj6O8A9ARMORti3gkqdzbg

ASX BRIEFS · Episode

20/05/2026

We are at AusMedTech26 in Perth today. If you are attending, join Orthocell CEO and Managing Director Paul Anderson in two key sessions:

👉11.25 AM – 12.20 PM
Paul will chair the panel discussion “Unlocking the next horizon in MedTech”, exploring the technologies, pathways and partnerships shaping the next wave of innovation across the sector.

👉4.30 PM
Paul will also join the panel discussion “How to balance the optimism for success with the reality of surviving setbacks when running a healthcare venture”, bringing his experience leading Orthocell through commercialisation, regulatory milestones and international expansion.

Across both sessions, Paul will share insights on building resilience, navigating challenges and driving long‑term growth in healthcare innovation.

$OCC

15/05/2026

Orthocell Ltd’s Chief Operations Officer, Alex McHenry, and Chief Financial Officer, Jim Piper, attended the Canaccord Genuity Australia Rapid Insights Conference in Sydney yesterday.

The conference brings institutional investors together with leading growth‑stage companies across key sectors, including Healthcare, where Orthocell continues to advance regenerative medicine innovation.

It was a valuable opportunity to share our growth strategy, connect with investors, and participate in roundtable discussions alongside 150 attendees exploring market trends and opportunities.

$OCC

14/05/2026

Orthocell is exhibiting at the International Congress of Orthoplastic Surgery (ICOS), sharing insights on Remplir™, our flagship nerve repair device.

🗓️ 14–16 May
📍 Grossman School of Medicine, New York University (NYU)

We look forward to connecting with colleagues in New York to discuss advances in peripheral nerve repair.

$OCC

07/05/2026

What’s On | Upcoming Events for OCC

Orthocell will be participating in several key surgical education events this month. Our team will be on site to discuss Remplir™, our flagship nerve repair device, and its role in peripheral nerve reconstruction.

International Congress of Orthoplastic Surgery
🗓️ May 14–16
📍 New York, NY
👤 Featuring Dr. Jacques Hacquebord

Global Nerve Foundation (GNF) Basic Nerve Course & Fellows Course
🗓️ May 16
📍 University of Utah

Washington University Nerve Course
🗓️ May 29–30
📍 Washington University Medical Center, St. Louis

We look forward to connecting with colleagues and advancing the conversation around nerve repair innovation.

$OCC

01/05/2026

What’s On | Upcoming Events for OCC in Australia

The Orthocell team is looking forward to attending these upcoming events across Australia.

Please drop by to learn more about our suite of Australian-made medical devices spanning nerve, tendon and bone repair.

AusBiotech | Medtech Unlocked�
🗓️ May 19–21, 2026�
📍 Perth

Orthocell Nerve Symposium�
🗓️ June 12�
📍 Sydney

2026 ASPS Plastic Surgery Congress
🗓️ July 24–25�
📍 Brisbane

We look forward to seeing you there.

$OCC

30/04/2026

Orthocell has shared that it has completed the first commercial sales of Remplir™ in the US75 million Canadian market, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device.

The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide majority national coverage across the Canadian market and position the Company to support surgeon and hospital adoption nationwide.

Orthocell has worked alongside its distributors on initial launch activities, including a KOL-led product roadshow across Canada (Vancouver to Toronto). The program featured Australian orthopaedic surgeon Dr Stuart Kirkham, who presented his clinical experience and use of Orthocell’s Remplir collagen nerve repair device to plastic and orthopaedic peripheral nerve surgeons. This activity supported product education and early engagement, contributing to the first commercial sales.

Following the Canadian launch, Orthocell will continue to work closely with its distributor network to onboard surgeons and establish active accounts, supported by the Company’s existing US-based marketing and medical education teams. This coordinated approach provides clinical engagement, training and operational efficiencies across the U.S. and Canada.

🔗 Read the ASX release: https://bit.ly/4tg90BW

$OCC